Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Ionis Pharmaceuticals

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PRAX-222

            Therapeutic Area: Neurology Product Name: PRAX-222

            Highest Development Status: IND Enabling Product Type: Small molecule

            Recipient: Praxis Precision Medicines

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 07, 2021

            Details:

            PRAX-222 is an antisense oligonucleotide that is designed to lower the expression levels of the protein encoded by the SCN2A gene in patients with SCN2A gain-of-function epilepsy.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AKCEA-APOCIII-LRx

            Therapeutic Area: Genetic Disease Product Name: ISIS 678354

            Highest Development Status: Phase III Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 01, 2020

            Details:

            The Phase 3 BALANCE study is a global, multi-center, randomized, double-blind, placebo-controlled study enrolling up to 60 patients with FCS.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AZD8233

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: ION449

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: AstraZeneca PLC

            Deal Size: $20.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration November 30, 2020

            Details:

            Ionis earned a milestone payment of $20 million from AstraZeneca for the Phase 2b clinical trial initiation of ION449. Ionis and AstraZeneca are collaborating on potential treatments for kidney disease, cardiometabolic disease and cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ION455

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ION455

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: AstraZeneca PLC

            Deal Size: $330.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement November 23, 2020

            Details:

            AstraZeneca has licensed ION455, an investigational antisense medicine being developed as a potential treatment for nonalcoholic steatohepatitis (NASH).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ION449

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: AZD8233

            Highest Development Status: Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: AstraZeneca PLC

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 13, 2020

            Details:

            Single doses resulted in potent, dose-dependent PCSK9 reductions of up to >90%, demonstrating best-in-class potential for the treatment of patients with high cholesterol at risk of cardiovascular disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ION541

            Therapeutic Area: Neurology Product Name: BIIB105

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 22, 2020

            Details:

            Veklury stops replication of sars-co v-2,thee virus that causes covid-19. Previously authorized bytheefdaa for emergency use to treat covid-19, Veklury is now the first and only approved covid-19 treatment in the united states.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IONIS-PKK-LRx

            Therapeutic Area: Infections and Infectious Diseases Product Name: ISIS 721744

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 15, 2020

            Details:

            Study will evaluate the effectiveness of IONIS-PKK-LRx in reducing the severity of respiratory complications in COVID-19 patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IONIS-ENAC-2.5Rx

            Therapeutic Area: Genetic Disease Product Name: IONIS-ENAC-2.5Rx

            Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 13, 2020

            Details:

            The study represents the first time an antisense medicine delivered directly to the lung via a nebulizer has shown a significant reduction in ENaC messenger RNA levels.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ASO-Centyrin drug conjugates

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Recipient: Aro Biotherapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement October 06, 2020

            Details:

            Ionis has exercised an option to obtain a license to an antisense oligonucleotide (ASO)-Centyrin drug conjugate. Ionis is using Aro’s CENTYRIN technology to enhance activity of ASOs via tissue-specific delivery for efficient inhibition of disease-causing RNAs and proteins.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Golimumab

            Therapeutic Area: Neurology Product Name: ION373

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 30, 2020

            Details:

            ION373 is an Ionis-owned investigational antisense medicine designed to stop the mutated gene from producing excess GFAP. Earlier this year, the European Medicines Agency (EMA) granted orphan drug designation to ION373.

            PharmaCompass